Medicure (OTCMKTS:MCUJF – Get Free Report) and Achieve Life Sciences (NASDAQ:ACHV – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, dividends, analyst recommendations and risk.
Profitability
This table compares Medicure and Achieve Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Medicure | -21.65% | -44.34% | -26.22% |
| Achieve Life Sciences | N/A | -193.49% | -111.88% |
Valuation & Earnings
This table compares Medicure and Achieve Life Sciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Medicure | $20.65 million | 0.40 | -$5.08 million | ($0.47) | -1.70 |
| Achieve Life Sciences | N/A | N/A | -$54.65 million | ($1.12) | -4.89 |
Medicure has higher revenue and earnings than Achieve Life Sciences. Achieve Life Sciences is trading at a lower price-to-earnings ratio than Medicure, indicating that it is currently the more affordable of the two stocks.
Institutional & Insider Ownership
33.5% of Achieve Life Sciences shares are held by institutional investors. 12.9% of Medicure shares are held by company insiders. Comparatively, 3.0% of Achieve Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Volatility and Risk
Medicure has a beta of 0.98, indicating that its stock price is 2% less volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 2.27, indicating that its stock price is 127% more volatile than the S&P 500.
Analyst Ratings
This is a breakdown of current recommendations for Medicure and Achieve Life Sciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Medicure | 0 | 0 | 0 | 0 | 0.00 |
| Achieve Life Sciences | 1 | 0 | 3 | 2 | 3.00 |
Achieve Life Sciences has a consensus target price of $14.67, suggesting a potential upside of 167.64%. Given Achieve Life Sciences’ stronger consensus rating and higher probable upside, analysts clearly believe Achieve Life Sciences is more favorable than Medicure.
About Medicure
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
About Achieve Life Sciences
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license and supply agreement with Sopharma AD and University of Bristol Achieve Life Sciences, Inc. is based in Vancouver, Canada.
Receive News & Ratings for Medicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medicure and related companies with MarketBeat.com's FREE daily email newsletter.
